Clinical Study

A Prospective, Randomized, Placebo-Controlled Study of a Combination of Simvastatin and Chemotherapy in Metastatic Breast Cancer

Figure 2

Survival for 60 months. The survival curve with reference to treatment groups (simvastatin vs. placebo) for MBC patients who were treated with palliative chemotherapy (carboplatin and vinorelbine). Median survival was estimated during a 60-month follow-up period using the Kaplan–Meier method. Statistical significance was assessed using the log-rank test, and two-tailed value of <0.05 was considered significant.